1. Yang JD, Hainaut P, Gores GJ et al (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16:589-604. https://doi/org/10.1038/s41575-019-0186-y
2. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L (2018) EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69:182-236. https://doi/org/10.1016/j.jhep.2018.03.019
3. Cersosimo RJ (2021) Systemic targeted and immunotherapy for advanced hepatocellular carcinoma. Am J Health Syst Pharm 78:187-202. https://doi/org/10.1093/ajhp/zxaa365
4. Kudo M (2020) Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer 9:640-662. https://doi/org/10.1159/000511001
5. Zhao B, Li L, Tumaneng K et al (2010) A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev 24:72-85. https://doi/org/10.1101/gad.1843810
6. Liu CY, Zha ZY, Zhou X et al (2010) The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem 285:37159-37169. https://doi/org/10.1074/jbc.M110.152942
7. Zanconato F, Forcato M, Battilana G et al (2015) Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol 17:1218-1227. https://doi/org/10.1038/ncb3216
8. Plouffe SW, Lin KC, Moore JL, 3rd et al (2018) The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell. J Biol Chem 293:11230-11240. https://doi/org/10.1074/jbc.RA118.002715
9. Zhang W, Li J, Wu Y et al (2018) TEAD4 overexpression promotes epithelial-mesenchymal transition and associates with aggressiveness and adverse prognosis in head neck squamous cell carcinoma. Cancer Cell Int 18:178. https://doi/org/10.1186/s12935-018-0675-z
10. Wu Y, Zheng Q, Li Y et al (2019) Metformin targets a YAP1-TEAD4 complex via AMPKalpha to regulate CCNE1/2 in bladder cancer cells. J Exp Clin Cancer Res 38:376. https://doi/org/10.1186/s13046-019-1346-1
11. Kang W, Huang T, Zhou Y et al (2018) miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis. Cell Death Dis 9:92. https://doi/org/10.1038/s41419-017-0134-0
12. Yu T, Song J, Zhou H et al (2021) Nuclear TEAD4 with SIX1 Overexpression is an Independent Prognostic Marker in the Stage I-III Colorectal Cancer. Cancer Manag Res 13:1581-1589. https://doi/org/10.2147/CMAR.S260790
13. Xia Y, Chang T, Wang Y et al (2014) YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PLoS One 9:e91770. https://doi/org/10.1371/journal.pone.0091770
14. Dent P, Booth L, Roberts JL et al (2019) Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. Oncogene 38:5890-5904. https://doi/org/10.1038/s41388-019-0849-8
15. Tao J, Calvisi DF, Ranganathan S et al (2014) Activation of beta-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology 147:690-701. https://doi/org/10.1053/j.gastro.2014.05.004
16. Zhang T, Zhang J, You X et al (2012) Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology 56:2051-2059. https://doi/org/10.1002/hep.25899
17. Wu H, Xiao Y, Zhang S et al (2013) The Ets transcription factor GABP is a component of the hippo pathway essential for growth and antioxidant defense. Cell Rep 3:1663-1677. https://doi/org/10.1016/j.celrep.2013.04.020
18. Misra JR, Irvine KD (2018) The Hippo Signaling Network and Its Biological Functions. Annu Rev Genet 52:65-87. https://doi/org/10.1146/annurev-genet-120417-031621
19. Bae SJ, Luo X (2018) Activation mechanisms of the Hippo kinase signaling cascade. Biosci Rep 38. https://doi/org/10.1042/BSR20171469
20. Wang C, Dou C, Wang Y et al (2019) TLX3 repressed SNAI1-induced epithelial-mesenchymal transition by directly constraining STAT3 phosphorylation and functionally sensitized 5-FU chemotherapy in hepatocellular carcinoma. Int J Biol Sci 15:1696-1711. https://doi/org/10.7150/ijbs.33844
21. Yu OM, Benitez JA, Plouffe SW et al (2018) YAP and MRTF-A, transcriptional co-activators of RhoA-mediated gene expression, are critical for glioblastoma tumorigenicity. Oncogene 37:5492-5507. https://doi/org/10.1038/s41388-018-0301-5
22. Yagi H, Asanoma K, Ohgami T et al (2016) GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer. Oncogene 35:4471-4480. https://doi/org/10.1038/onc.2015.505
23. Zanconato F, Cordenonsi M, Piccolo S (2016) YAP/TAZ at the Roots of Cancer. Cancer Cell 29:783-803. https://doi/org/10.1016/j.ccell.2016.05.005
24. Lee KP, Lee JH, Kim TS et al (2010) The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A 107:8248-8253. https://doi/org/10.1073/pnas.0912203107
25. Song H, Mak KK, Topol L et al (2010) Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A 107:1431-1436. https://doi/org/10.1073/pnas.0911409107
26. Wang EY, Cheng JC, Thakur A et al (2018) YAP transcriptionally regulates ErbB2 to promote liver cell proliferation. Biochim Biophys Acta Gene Regul Mech. https://doi/org/10.1016/j.bbagrm.2018.07.004
27. Cai WY, Lin LY, Hao H et al (2017) Yes-associated protein/TEA domain family member and hepatocyte nuclear factor 4-alpha (HNF4alpha) repress reciprocally to regulate hepatocarcinogenesis in rats and mice. Hepatology 65:1206-1221. https://doi/org/10.1002/hep.28911
28. Marquard S, Thomann S, Weiler SME et al (2020) Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis. Cell Commun Signal 18:166. https://doi/org/10.1186/s12964-020-00634-6
29. Hilger D, Masureel M, Kobilka BK (2018) Structure and dynamics of GPCR signaling complexes. Nat Struct Mol Biol 25:4-12. https://doi/org/10.1038/s41594-017-0011-7
30. Gundamaraju R, Lu W, Azimi I et al (2020) Endogenous Anti-Cancer Candidates in GPCR, ER Stress, and EMT. Biomedicines 8. https://doi/org/10.3390/biomedicines8100402
31. Zhou X, Wang S, Wang Z et al (2015) Estrogen regulates Hippo signaling via GPER in breast cancer. J Clin Invest 125:2123-2135. https://doi/org/10.1172/JCI79573
32. Cai H, Xu Y (2013) The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. Cell Commun Signal 11:31. https://doi/org/10.1186/1478-811X-11-31
33. Cheng JC, Wang EY, Yi Y et al (2018) S1P Stimulates Proliferation by Upregulating CTGF Expression through S1PR2-Mediated YAP Activation. Mol Cancer Res 16:1543-1555. https://doi/org/10.1158/1541-7786.MCR-17-0681
34. Mo JS, Yu FX, Gong R et al (2012) Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). Genes Dev 26:2138-2143. https://doi/org/10.1101/gad.197582.112
35. Zhou PJ, Xue W, Peng J et al (2017) Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathway. J Exp Clin Cancer Res 36:139. https://doi/org/10.1186/s13046-017-0609-y
36. Nag JK, Bar-Shavit R (2018) Transcriptional Landscape of PARs in Epithelial Malignancies. Int J Mol Sci 19. https://doi/org/10.3390/ijms19113451
37. Zheng CH, Chen XM, Zhang FB et al (2018) Inhibition of CXCR4 regulates epithelial mesenchymal transition of NSCLC via the Hippo-YAP signaling pathway. Cell Biol Int 42:1386-1394. https://doi/org/10.1002/cbin.11024
38. Qin Q, Xu Y, He T et al (2012) Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res 22:90-106. https://doi/org/10.1038/cr.2011.144
39. Li Z, Chen B, Dong W et al (2019) MKL1 promotes endothelial-to-mesenchymal transition and liver fibrosis by activating TWIST1 transcription. Cell Death Dis 10:899. https://doi/org/10.1038/s41419-019-2101-4